ScreenerHero

MANEVeradermics Incorporated Common Stock

NYSE · US · Healthcare · Biotechnology · veradermics.com
102.82USD-7.56%Mkt Cap: 4.30B $P/E: —

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.30B $
Enterprise Value3.48B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-70.00M $
Revenue/Share—
Last Price102.82 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees37
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-38.26
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B9.83
EPS (TTM)-2.50
EPS (Forward)-2.69
52W Range
32.0071% of range131.24
52W High131.24 USD
52W Low32.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE57.84%
ROA-45.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-71.60M $
CapEx (TTM)24.00K $
FCF Margin—
FCF Yield—
Net Debt-819.47M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.00
Current Ratio70.53
Quick Ratio70.25
Book Value/Sh10.46 USD
Cash/Share19.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)163.50 USD
Upside (mean)+59.0%
Target Range135.00 USD – 182.00 USD
$135.00+59.0% to mean$182.00
# Analysts6
Ownership
Shares Out.41.78M
Float31.84M
Insiders2.49%
Institutions98.24%
Short Interest
Short Ratio7.6d
Short % Float17.72%
Short % Out.11.54%
Shares Short4.82M
Short (prev mo.)3.81M
Technical
SMA 50110.54 (-7.0%)
SMA 20086.39 (+19.0%)
Beta—
S&P 52W Chg19.18%
Avg Vol (30d)701.15K
Avg Vol (10d)658.26K
Technical Indicators
RSI (14)43.3
MACD-0.5759
MACD Signal-0.2445
MACD Hist.-0.3315
BB Upper116.43 USD
BB Middle109.20 USD
BB Lower101.97 USD
BB Width13.24%
ATR (14)7.426 USD
Vol Ratio (20d)0.46x